Biofrontera AG/  DE000A4BGGM7  /

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE 0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through local partners. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® for the regenerative care of reddened and inflamed skin. Biofrontera developed a line of cosmeceutical products for damaged skin under the Belixos brand. The product portfolio includes the Belixos® cream, Belixos LIQUID®, Belixos® GEL and DayCare cream Belixos® PROTECT.